• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Diabetes and Metabolism

    Diabetes and Metabolism

    JournalISSN 1262-3636eISSN 1878-1780中科院 医学 2区

    年发文量

    研究主题

    论文(12278)

    排序
    1NewReal-world Effectiveness of Tirzepatide in Individuals with Obesity: Weight Response, Treatment-Related Factors and Diabetes Status
    Maria Eugenia Parrotta, Ilaria Milani, Marianna Chinucci, Francesco Occhipinti, Elena Gintoli, Francesco Franco, Giulia Sanci, Paolo Sbraccia, Danila Capoccia, Valeria Guglielmi

    Introduction Tirzepatide reduces body weight and improves glycemic control, but real-world comparisons between individuals with obesity with and without type 2 diabetes (T2D) remain limited, as well as the potential influence on weight-loss response of baseline characteristics (especially sex and previous treatment exposure). We aimed to compare anthropometric and metabolic outcomes in these populations, as well as treatment persistence, discontinuation, and the influence of prior GLP-1 receptor agonist (GLP-1 RA) exposure. Methods This retrospective multicenter study included adults with overweight/obesity without T2D (Ob) or with T2D (ObT2D) treated with tirzepatide. Data were collected at baseline and after 2–4 (T1), 5–8 (T2), and 9–15 (T3) months. Longitudinal changes were assessed using linear mixed-effects models, and multivariable analyses identified predictors of weight loss. Results Ob participants (n = 210, 74.8% female) were younger, had higher BMI, better glycemic control, and less previous GLP-1RA exposure than ObT2D participants (n = 378, 49.7% female) (45.7%vs 79.3%; p < 0.001). Weight loss was greater in Ob than ObT2D at all follow-ups (−5.0% vs −2.8%, −10.1% vs −3.3%, and −14.2% vs −4.7%; all p ≤ 0.011), with mixed-effects models confirming different trajectories. This difference was attenuated and no longer statistically significant when analyses were restricted to treatment-naïve participants. Prior GLP-1RA exposure was independently associated with lower weight loss, while an interaction between prior GLP-1RA exposure and T2D status emerged at longer follow-up. No effect modification by sex or age was clearly detectable in this cohort. Discontinuation was more frequent in Ob, with adverse events, and financial barriers among the main reported reasons. Adverse events occurred in 16.9%, were mainly mild, transient gastrointestinal events, more frequent in Ob than ObT2D (26.9%vs 11.1%; p < 0.001). Conclusions Tirzepatide was effective and well tolerated in routine practice. Greater weight loss occurred in obesity without T2D, while prior GLP-1RA exposure was independently associated with a reduced weight response. Previous GLP1-RA exposure may partly account for the different weight-loss trajectories observed between obesity with and without T2D. Residual differences at longer follow-up may reflect additional unmeasured clinical, metabolic, and treatment-related factors.

    2027
    引用
    AI阅读
    加入学术空间
    2NewEfficacy and Safety of the Dual SGLT1 and SGLT2 Inhibitor JP-2266 in Type 2 Diabetes: a Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study (diabetes Metab J, Published Online July 29, 2026).
    Chan Zhang
    2027
    引用
    AI阅读
    加入学术空间
    3NewAutomated Insulin Delivery and Lower Burden of Hypoglycemia in Type 1 Diabetes: a Prospective Analysis of the BETTER Registry
    Meryem K. Talbo,Tricia M. Peters,Jean François Yale,Courtney A. South,Remi Rabasa-Lhoret,Anne-Sophie Brazeau
    2026
    引用
    AI阅读
    加入学术空间
    4NewOne Patient, Two Glucose Profiles: Arm-Dependent Continuous Glucose Monitoring Discordance in Hemiplegia
    Philippe Oriot,Fabian O. Lurquin,Michel P. Hermans
    2026
    引用
    AI阅读
    加入学术空间
    5NewRisk of Incident Type 2 Diabetes with Romosozumab Versus Denosumab in Patients with Osteoporosis: A Global Real-World Cohort Study
    Chui-Jia Farn, I-Ching Chiang,Hung-Kuan Yen, Mao-Yi Yang,I-Hsin Chen, I-Weng Yen,Tzu-Hao Tseng,Shau-Huai Fu,Chen-Yu Wang

    Background Antiosteoporotic agents may influence glucose regulation. Although denosumab has been evaluated for its potential effects on diabetes-related outcomes, the metabolic effects of romosozumab, a sclerostin inhibitor, remains unclear. Methods This retrospective cohort study included patients aged ≥45 years with osteoporosis and no prior diabetes who initiated romosozumab or denosumab between 2019 and 2024 from the TriNetX network. An active-comparator, new-user design compared romosozumab users with denosumab users. The primary outcome was incident type 2 diabetes (T2D). Secondary outcomes included broader diabetes diagnoses, initiation of antidiabetic medications, and laboratory-defined diabetes. Treatment groups were balanced using 1:1 propensity score matching (PSM). Cox proportional hazards models, Kaplan–Meier analyses with log-rank tests, calendar time analyses, and multiple sensitivity analyses were performed. Results After propensity score matching, 6581 patients were analyzed in each treatment group. Romosozumab initiation was not associated with a significant difference in incident T2D compared with denosumab (HR, 0.93; 95% CI, 0.78–1.12; log-rank p = 0.468). Similarly, no significant differences were observed for broader diabetes diagnoses (HR, 1.01; 95% CI, 0.86–1.20), antidiabetic medication initiation (HR, 1.15; 95% CI, 0.95–1.40), or laboratory-defined diabetes (HR, 0.97; 95% CI, 0.77–1.21). Conclusions Romosozumab was not associated with an increased risk of incident T2D or other diabetes-related outcomes compared with denosumab. These findings were supported by calendar-year-specific analyses, although residual confounding and differential follow-up warrant cautious interpretation. Future prospective studies are needed to clarify the metabolic effects of sclerostin inhibition.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 12278 篇论文

    高被引作者

    作者引用发文
    André J Scheen5378151
    B. Guerci2423140
    E DUSSAULX24033
    MD APPAY24031
    Alain Zweibaum24034
    M Kedinger24039
    B Lacroix24035
    Patricia Simon-Assmann24036
    N Triadou24033
    S ROBINELEON24031

    高产作者

    作者引用发文
    Paul Valensi2231316
    Emmanuel Cosson1079209
    Michel Marre2062164
    André J Scheen5378151
    B. Guerci2423140
    Beverley Balkau2265133
    Bruno Vergès1448131
    Guillaume Charpentier1167125
    Penfornis Alfred609121
    S. Halimi1402118

    相关期刊

    Acta diabetologica latina
    Journal of Diabetes and its Complications
    Diabetes, Obesity and Metabolism
    Metabolic syndrome and related disorders
    Diabetology & metabolic syndrome
    Journal of diabetes
    World journal of diabetes
    Diabetes & metabolism journal
    Journal of diabetes investigation
    ENDOCRINOLOGY DIABETES & METABOLISM